Recently, the new traditional Chinese medicine (TCM) compound preparation Qijiao Tiaojing Granule of Hunan Anbang Pharmaceutical Co., Ltd. was approved for marketing by China NMPA.

The drug is composed of nine ingredients, including Radix Astragali, Colla Corii Asini, , Radix Codonopsis, and Radix Paeoniae Alba etc. It has the effect of nourishing Qi, replenishing blood, stopping bleeding, and regulating menstruation. It is indicated to treat prolonged menstrual periods caused by intrauterine device insertion with TCM syndrome differentiation of Qi and blood deficiency.

Multicenter, randomized, double-blinded, parallel group and positive TCM-controlled clinical trials showed that the recovery rate and improvement rate were 31.82% and 63.64% respectively in the experimental group, and 12.00% and 38.00% in the controlled group, demonstrating that the differences between groups are of statistical significance. The marketing of the drug provides new treatment option for patients.